Overexpression of RSPO2, RSPO3, and RSPO4 has been reported in breast cancer patients, in particular in triple‐negative tumors, where enhanced RSPO2 expression was associated with reduced metastasis‐free survival [30, 31]. This evidence concerns the gene RSPO4 and breast carcinoma.